Medtronic Raises 2027 Forecasts Amid Surging Heart Device Demand

Medtronic has revised its fiscal 2027 projections upwards, fueled by robust demand for its heart devices used in complex cardiovascular procedures. The company announced this adjustment on Tuesday, highlighting the expansion of its product portfolio and strategic market investments as key factors.

Strategic Investments and Market Expansion

In a significant move, Medtronic has committed $80 million to Pi-Cardia, a heart-valve repair device maker, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States.

CEO Geoff Martha emphasized the importance of these investments during a post-earnings call, noting the complementary nature of Cornerstone’s Sentire robotic system to Medtronic’s existing Hugo device. He pointed out the low penetration rates of soft tissue robotic surgery in emerging markets, suggesting substantial growth potential.

Financial Performance and Forecast Adjustments

Medtronic's financial outlook reflects these strategic moves. The company has increased the lower end of its fiscal 2027 adjusted per share profit forecast to $5.94, up from $5.90, while maintaining the upper end at $6. Additionally, Medtronic now expects annual organic revenue growth between 7.25% and 7.75%, exceeding its previous forecast of 6.75% to 7.25%.

Chief Financial Officer Thierry Pieton noted that the company benefited from tariff refunds that nearly offset the duties paid during the quarter. However, future refunds have not been factored into the company's projections.

Strong Quarter for Cardiovascular Segment

Medtronic's cardiovascular segment experienced a notable 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was largely driven by the company's pulsed field ablation portfolio, which is used to treat irregular heart rhythms and saw an impressive 88% increase.

The company reported an adjusted quarterly per share profit of $1.45 on revenues of $9.76 billion, surpassing analysts' expectations of $1.39 per share on $9.55 billion in sales, according to data compiled by LSEG.

Martha emphasized the company's strategy of prioritizing high-growth segments within the medical technology industry, focusing on areas with large patient pools and substantial market potential.